Julia M. Carlson

Julia M. Carlson

Auto-generated profile, based on publicly available information

Julia M. Carlson

Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2023 in Neurology
Verified
Journal Article
Closed access
PDF file
MJMichelle C. Johansen
Michelle C. Johansen
JCJinyu Chen
Jinyu Chen
ASAndrea Lauren Christman Schneider
Andrea Lauren Christman Schneider
JCJulia Carlson
Julia Carlson
THTaylor Haight
Taylor Haight
SKSilvia Koton
Silvia Koton
Background and Objectives: Disability after stroke occurs across ischemic stroke subtypes, with a suggestion that embolic strokes are more devastating. Whether this difference is as a result of differences in comorbidities, or differences in severity at the time of the stroke event is not known. The primary hypothesis was that participants with embolic stroke would have more severe stroke at the time of admission, and higher risk of mortality, compared to thrombotic stroke participants even with consideration of confounders over time, with a secondary hypothesis that this association would differ by race and sex. Methods: Atherosclerosis Risk in Communities (ARIC) study participants with incident adjudicated ischemic stroke, stroke severity and mortality data, and complete covariates were included. Multinomial logistic regression models determined the association between stroke subtype (embolic versus thrombotic) and admission NIHSS category [minor (≤5), mild (6-10), moderate (11-15), severe (16-20), very severe (>20)] adjusted for covariates from visits most-proximal to the stroke. Separate ordinal logistic models evaluated for interaction by race and sex. Adjusted Cox proportional hazard models estimated the association between stroke subtype and all-cause mortality (through December 31, 2019). Results: Participants (N=940) were mean age 71years [SD=9] at incident stroke, 51% female and 38% Black. Using adjusted multinomial logistic regression, the risk of having a more severe stroke (reference NIHSS ≤5) was higher among embolic stroke versus thrombotic stroke patients, with a step-wise increase for embolic stroke patients when moving from mild (OR=1.95, 95%CI=1.14-3.35) to very severe strokes (OR=4.95, 95%CI=2.34-10.48). After adjusting for atrial fibrillation, there was still a higher risk of having a worse NIHSS among embolic versus thrombotic strokes, but with attenuation of effect (very severe stroke OR=3.91, 95%CI=1.76-8.67). Sex modified the association between stroke subtype and severity (embolic versus thrombotic stroke, p-interaction=0.03, per severity category, females OR=2.38, 95%CI=1.55-3.66; males OR=1.75, 95%CI=1.09-2.82). Risk of death (median follow-up 5 years, IQR 1-12) was also increased for embolic versus thrombotic stroke patients (HR 1.66, 95%CI 1.41-1.97). Discussion: Embolic stroke was associated with greater stroke severity at the time of the event, and higher risk of death versus thrombotic stroke, even after careful adjustment for patient-level differences.

1 March 2022 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
PDF file
JCJulia M. Carlson
Julia M. Carlson
EEEric W. Etchill
Eric W. Etchill
CEClare Angeli G. Enriquez
Clare Angeli G. Enriquez
APAnna Peeler
Anna Peeler
GWGlenn J. Whitman
Glenn J. Whitman
Sung-Min ChoSung-Min Cho
Sung-Min Cho

15 February 2023 in The Neurohospitalist
Verified
Journal Article
Closed access
JCJulia M. Carlson
Julia M. Carlson
BMBradley J. Molyneaux
Bradley J. Molyneaux
JLJong Woo Lee
Jong Woo Lee
Cenobamate is an effective new adjunctive antiseizure medication (ASM) for treatment resistant focal epilepsy. It has broad spectrum anticonvulsant activity and may be a useful medication for super refractory status epilepticus (SRSE), but has not yet been studied in generalized seizures or an inpatient setting. Here we describe 2 SRSE cases where cenobamate was added safely to other treatments. It was uptitrated slowly to reduce the risk of hypersensitivity reactions which have been observed previously with rapid increasing dosages. Both patients achieved seizure control and liberation from intensive care. They have remained seizure free with continued treatment and have not experienced any side effects attributable to cenobamate. Cenobamate warrants further examination in patients with refractory status epilepticus.

27 September 2023 in Seminars in Neurology
Verified
Journal Article
Closed access
PDF file
JCJulia M. Carlson
Julia M. Carlson
DLDavid J. Lin
David J. Lin
Patients with prolonged disorders of consciousness (DOCs) longer than 28 days may continue to make significant gains and achieve functional recovery. Occasionally, this recovery trajectory may extend past 3 (for nontraumatic etiologies) and 12 months (for traumatic etiologies) into the chronic period. Prognosis is influenced by several factors including state of DOC, etiology, and demographics. There are several testing modalities that may aid prognostication under active investigation including electroencephalography, functional and anatomic magnetic resonance imaging, and event-related potentials. At this time, only one treatment (amantadine) has been routinely recommended to improve functional recovery in prolonged DOC. Given that some patients with prolonged or chronic DOC have the potential to recover both consciousness and functional status, it is important for neurologists experienced in prognostication to remain involved in their care.

1 February 2025 in Neurology Clinical Practice
Verified
Journal Article
Closed access
JCJulia M. Carlson
Julia M. Carlson
GGGalina Gheihman
Galina Gheihman
KEKristi Emerson
Kristi Emerson
HAHaitham S. Alabsi
Haitham S. Alabsi
WKW. Taylor Kimberly
W. Taylor Kimberly
DLDavid J. Lin
David J. Lin
Despite increasing interest in post-intensive care unit (ICU) clinical care and management, there have been limited descriptions focused on the post-neurologic (neuro)-ICU population. Here, we describe the design of a post-neuro-ICU Neurorecovery Clinic (NRC) and present data collected regarding the clinic's population, referrals, visits, and clinician satisfaction. This is a single-institution experience with a NRC designed to provide an infrastructure for post-ICU care to patients recovering from acute neurologic disorders or systemic conditions with neurologic sequelae. The clinic offers 2 visit types with different frequencies: a weekly visit and a monthly multidisciplinary visit. This study assessed clinical utilization and clinician perspectives regarding the clinic. Data on clinic referrals, no-show frequency, visit types, and diagnoses for both weekly and monthly visits were collected. A survey was conducted to assess clinician satisfaction and perspectives. Qualitative thematic analysis was performed to identify major themes among survey free responses. In a 2-year period, 225 patients were referred from the Massachusetts General Hospital neuro-ICU to the NRC. Of those, 105 (47%) were seen in clinic for at least one visit. The most common reasons for loss to follow-up were no shows (38%) and noncontracted insurance (21%). Twenty percent of visits were in-person (the rest were by telehealth). Forty-eight percent were new patients compared with return visits. The most common diagnoses were other (36%), ischemic stroke (26%), and traumatic brain injury (17%). An additional monthly multidisciplinary clinic has seen 14 patients with one no show. Clinicians found their experience in the NRC valuable. Identified benefits included interdisciplinary collaboration, being a more well-rounded and better clinician, improving effectiveness in managing post-ICU problems, and influencing ICU prognosis. Clinicians' greatest challenge was navigating resource limitations for patients. A postneuro-ICU NRC is a feasible model of care delivery for patients after severe acute neurologic disorders. Patients with a broad variety of diagnoses were seen in a 2-year period. Providers valued their clinic time and experiences. Future studies should evaluate whether this model of care improves patients' postneuro-ICU outcomes.

5 March 2026 in New England Journal of Medicine
Verified
Journal Article
Closed access
SGSalma M.A. Gayed
Salma M.A. Gayed
MMMichael P. Motley
Michael P. Motley
JCJulia M. Carlson
Julia M. Carlson
KLKiersten S. Lupu
Kiersten S. Lupu
NMNikolaos Mavrogiorgos
Nikolaos Mavrogiorgos